Skip to main content

Cancer from a donor organ: what transplant patients should know

How cancer can pass from a donor organ, what U.S. transplant policy requires of donor and transplant teams, and the deadlines and immunities that apply in Pennsylvania and New Jersey.

A tumor can pass from an organ donor to the recipient through the transplanted organ.1 It can also surface late: in a review of 73 published cases among liver, heart, lung and multi-organ recipients, the median time to diagnosis was 8 months.1 This guide explains how that happens, what the donor and transplant teams had to do, and the deadlines in Pennsylvania and New Jersey.

About 1 in 2,000

UK guidance's estimate of the risk that a donor not known to have cancer passes a cancer to a recipient2

2.6 per 10,000

transplant recipients in the U.S. with an unexpected proven or probable donor-derived malignancy, 2012 to 20176

24 hours

The deadline in current U.S. national transplant policy (2026) for reporting positive donor test results that arrive after procurement3

How can cancer come from a donor organ, and how rare is it?

Cancers from a donor may be divided into two kinds.2 A donor-transmitted cancer was present in the donated organ and tissue at transplantation.2 A donor-derived cancer is of donor origin but develops new in the graft after transplantation.2 Both must be distinguished from the recipient's own cancers.2

In the United States, the Disease Transmission Advisory Committee (DTAC) received 2,185 reports from 2008 through 2017 and classified 335 (15%) as proven or probable donor transmission events.6 Infections were the most common transmissions (67%), followed by malignancies (29%).6 The committee's report uses "donor-derived disease" in a broader sense than the UK guidance, for any disease passed on from a donor, infections included.6

For 2012 to 2017, most of the risk of unexpected donor-derived disease came from infection.6

Figure 1Unexpected donor-derived disease in U.S. transplant recipients, by type, 2012 to 2017.6

051015142.61.2InfectionMalignancyOther processesType of proven or probable donor-derived diseaseCases per 10,000 transplant recipients051015142.61.2InfectionMalignancyOtherprocessesType of proven or probable donor-derived diseaseCases per 10,000 transplant recipients
Unexpected donor-derived disease in U.S. transplant recipients, by type, 2012 to 2017. Cases per 10,000 transplant recipients by type of proven or probable donor-derived disease.
Type of proven or probable donor-derived diseaseDTAC, 2012 to 2017
Infection14
Malignancy2.6
Other processes1.2
Source: Kaul DR et al., Ten years of donor-derived disease: A report of the Disease Transmission Advisory Committee (OPTN), section 3.6; unexpected proven or probable donor-derived disease, 2012 to 2017; retrieved 2026-11-10.

UK registry data for 2001 to 2010 cover 30,765 transplants from 14,986 deceased donors.2 Eighteen recipients developed cancers of donor origin, from 16 donors (0.06%).2 Fifteen of those cancers were donor-transmitted (0.05%) and three were donor-derived (0.01%).2 None of the donors who transmitted cancer were known to have cancer at donation, and the UK guidance says there is no category of zero risk.2

The review of 73 cases, published in Transplant International in February 2022, covered liver, heart, lung and multi-organ recipients and found that 42% were widespread at diagnosis.1 Mortality in those cases was 75%, though the authors say publication bias and clinical heterogeneity (wide differences between cases) limit the evidence.1 Kidney and pancreas recipients were outside that figure. For them, the same review says the usual treatment is stopping immunosuppression and then removing the transplanted organ, which can lead to remission even when the cancer has spread widely.1

What was supposed to protect you?

OPTN policy text only. No patient, donor or case is shown.

The chain of safeguards from donor to recipient

Seven links in this chain, each a duty in current (2026) Organ Procurement and Transplantation Network (OPTN) policy, from screening the donor to reviewing a reported event. Choose a link to read each rule in plain words and in its own text. In OPTN policy, the host OPO is the OPO responding to a deceased organ donor referral from a hospital.3

Link 1Host OPOBefore transplant

Screen the donor

OPTN Policies 2.3 (evaluating and screening potential deceased donors) and 2.4 (deceased donor medical and behavioral history)3

In plain words

  • The host OPO must attempt to obtain the deceased donor's medical and behavioral history from one or more people familiar with the donor.3
  • The host OPO must review the deceased donor's medical record.3
  • The host OPO must complete a physical examination of the deceased donor.3
  • The donor's history must include any testing and laboratory results used to identify transmissible diseases or malignancies, treated and untreated.3

“Any testing and laboratory results used to identify the presence of transmissible diseases or malignancies, treated and untreated, or any other known condition that may be transmitted by the deceased donor organ and may reasonably impact the recipient.”

The policy's own words3

Link 3Host OPOAfter procurement24 hours3

Report donor results after procurement

OPTN Policy 15.4.A (host OPO requirements for reporting post-procurement donor results)3

In plain words

  • The host OPO must report all positive test results and other relevant information it receives about each donor after procurement.3
  • The report goes to the Patient Safety Contacts at every transplant program that received the donor's organs.3
  • That report is due as soon as possible but no later than 24 hours after receipt.3

“through the OPTN Donor Data and Matching System as soon as possible but no later than 24 hours after receipt.”

The policy's own words3

Link 4Transplant programAfter procurement

Notify recipients and follow them

OPTN Policy 15.5.A (transplant program requirements for discovery of potential transmission of an unexpected donor pathogen, disease or malignancy)3

When it applies

Under OPTN policy, a potential transmission of a malignancy is unexpected if the transplant program did not know of it by the time of donor cross-clamp.3

In plain words

  • When a transplant program finds results indicating an unexpected malignancy from donor testing, it must notify its recipients of the risk or confirmation.3
  • The program must follow the notified recipients for the potential development of the disease or malignancy after transplant.3

“Follow the notified recipients for the potential development of the disease or malignancy after transplant.”

The policy's own words3

Link 5Transplant programAfter transplant24 hours3

Report a suspected donor-derived transmission

OPTN Policy 15.5.B (transplant program requirements for reporting discovery of potential transmission of an unexpected recipient pathogen, disease or malignancy)3

When it applies

One listed recipient is a non-lung organ recipient who is suspected to have, is confirmed positive for, or has died from any unexpected potential transmissible pathogen, disease or malignancy.3

In plain words

  • Transplant programs are required to report the discovery of a potential transmission for the recipients the policy lists.3
  • For that recipient, there must also be substantial concern that the suspected or confirmed pathogen, disease or malignancy could be from the transplant organ.3
  • A transplant program must report a suspected donor-derived transmission through the OPTN Patient Safety Reporting Portal within 24 hours after learning of the event.3

“Report the event through the OPTN Patient Safety Reporting Portal within 24 hours after learning of the event.”

The policy's own words3

Link 6Host OPOAfter transplant24 hours3

Alert every program and tissue bank

OPTN Policy 15.4.B (host OPO requirements for reporting post-procurement discovery of recipient disease or malignancy)3

When it applies

The host OPO has further duties when it is notified that a recipient is suspected to have, is confirmed positive for, or dies from a potential transmissible disease, infection or malignancy and there is substantial concern that it could be from the transplanted organ.3

In plain words

  • In that case the host OPO must communicate relevant test results and diagnosis, within 24 hours of receipt, to every transplant program and tissue bank that received organs or tissue from the donor.3

“24 hours after receipt, to all transplant programs' primary Patient Safety Contacts and tissue banks that received organs or tissue from the donor.”

The policy's own words3

Link 7Host OPO with OPTN patient safety staffReview

Review the event

OPTN policy, and the OPTN's Disease Transmission Advisory Committee (DTAC)36

In plain words

  • For each reported event, the host OPO must contribute to a follow-up review in partnership with OPTN patient safety staff.3
  • The Disease Transmission Advisory Committee (DTAC) was created to review and classify reports of potential disease transmission.6
  • From 2008 through 2017, the OPTN's Disease Transmission Advisory Committee (DTAC) received 2185 reports, and 335 (15%) were classified as proven or probable donor transmission events.6

“Contribute to a follow up review of the event, in partnership with OPTN patient safety staff.”

The policy's own words3

The federal layer, from January 4, 2027

Under the amended federal quality rule for OPOs, adverse events include transmission of a disease from a donor to an organ recipient, such as the transmission, dissemination and seeding of malignancies.src The amended rule takes effect on January 4, 2027.src

Two published figures, each on its own scale

Each figure keeps its own country, period and definition. They are not added, averaged or compared here.

UK guidance (SaBTO)

About 1 in 2,000

The UK guidance puts the risk of cancer transmission from a donor not previously known to have cancer at around 0.05%, or 1 in 2000.2

2,000 dots. One is marked.

  • UK registry data cover 30,765 transplants from 14,986 deceased donors between January 1, 2001 and December 31, 2010.2
  • Eighteen recipients developed cancers of donor origin, from 16 donors (0.06%).2
  • Of those cancers, fifteen were donor-transmitted cancers (0.05%) and three were donor-derived cancers (0.01%).2
  • None of the donors from whom cancer was transmitted were known to have cancer at donation.2

U.S. Disease Transmission Advisory Committee

2.6 per 10,000 recipients

The rate of unexpected proven or probable donor-derived malignancy was 2.6 per 10,000 recipients.6 The committee calculated the 2012 to 2017 risk of unexpected donor-derived disease across transplant recipients.6

10,000 cells. 2.6 are marked: two whole cells and six tenths of a third.

Close-up of the marked row, magnified

The two sources use “donor-derived” differently. In the UK guidance: Donor-derived cancers are of donor origin but develop new in the graft after transplantation.2 The U.S. committee also counts infections as donor-derived disease: The rate of unexpected proven or probable donor-derived infection was 14.0 per 10,000 recipients.6

The UK guidance says there is no category of zero risk.2

Choose a link to see who must act under current Organ Procurement and Transplantation Network (OPTN) policy (2026), and when, from the donor's history and testing to the 24-hour reports and the review of each reported event.3 Below the chain, two published figures sit on separate scales: the UK estimate of about 1 in 2,000 for a donor not known to have cancer,2 and the U.S. committee's rate of 2.6 per 10,000 recipients.6
What this shows
Who must do what under current OPTN policy before and after a transplant, the duties that run on a 24-hour clock, and two published figures for cancer passed on from a donor (a UK estimate of transmission risk and a U.S. rate of donor-derived malignancy), each on its own scale.
What it does not show
Whether any duty was met in any case, or what follows if it was not. The order of the links is a reading aid and does not show which party acts first in a given case. The UK and U.S. figures cover different populations, periods and definitions and are not combined.

Before the transplant. Under current OPTN policy, Policy 2.3 requires the host organ procurement organization (OPO) to seek the deceased donor's medical and behavioral history from people familiar with the donor, review the medical record and complete a physical examination.3 The host OPO is the OPO responding to a hospital's deceased-donor referral.3 Under Policy 2.4, that history must include any testing and laboratory results used to identify transmissible diseases or malignancies, treated and untreated.3 Policy 2.4 sets what the history must record, including the results of testing that was done; it names no particular cancer screen.3

Risograph illustration of a lab bench with test tubes and a microscopeIllustration
Donor testing.

Informed consent. Under OPTN Policy 15.3.A, transplant programs must inform candidates of the general risks of potential transmission of malignancies and disease from organ donors.3 That includes telling them that malignancies may be identified and transmitted after transplant.3 The program must obtain informed consent before transplant and document it in the medical record.3

There is no comprehensive way to screen deceased and living donors for all transmissible diseases.”3

From OPTN Policy 15.3.A, on the risks transplant programs must explain to candidates before a transplant.3

After the transplant. Under Policy 15.4.A, the host OPO must report positive donor results it receives after procurement to every program that received the donor's organs, no later than 24 hours after receipt.3 Under Policy 15.4.B, if the OPO learns that a recipient is suspected to have a potential transmissible malignancy and there is substantial concern that it could be from the transplanted organ, it must share relevant results within 24 hours with every program and tissue bank that received the donor's organs or tissue.3 Under Policy 15.5.A, a program that finds an unexpected malignancy in donor testing must notify its recipients and follow them for the potential development of the disease.3 A malignancy is unexpected if the program did not know of it by the time of donor cross-clamp, a step in the surgery that recovers the organs.3 Under Policy 15.5.B, a program must report through the OPTN Patient Safety Reporting Portal, within 24 hours after learning of the event, when a non-lung organ recipient is suspected to have an unexpected potential transmissible malignancy and there is substantial concern that it could be from the transplanted organ.3

What are your rights in Pennsylvania and New Jersey?

Deadlines decide whether a claim can be heard at all, so they come first below. Both states also set filing rules for malpractice claims, and both states' anatomical gift laws protect people who act in good faith.

Risograph illustration of a desk with a file folder, binder and calendarIllustration
Records and deadlines.

The deadlines.

  1. The two-year limits

    Under 42 Pa.C.S. § 5524(2), a Pennsylvania action to recover damages for injuries to the person caused by the negligence of another generally must be commenced within two years.4 Under N.J.S.A. 2A:14-2(a), a New Jersey personal injury action generally must be commenced within two years after the cause of action accrued (legally arose).5 Shorter deadlines can apply to some claims.5

  2. If you reasonably did not know (Pennsylvania)

    As the Supreme Court of Pennsylvania explained in Nicolaou v. Martin, decided October 17, 2018, "the discovery rule tolls the statute of limitations where the plaintiff is reasonably unaware that he has been injured and that his injury has been caused by another party's conduct".7 Tolling means the two-year clock is held off.

  3. If you reasonably did not know (New Jersey)

    In Lopez v. Swyer, 62 N.J. 267 (1973), the Supreme Court of New Jersey described the discovery rule: in an appropriate case, a claim does not accrue until the injured person discovers, or by reasonable diligence and intelligence should have discovered, that they may have a basis for a claim.8 The judge decides whether the rule applies, ordinarily at a preliminary hearing outside the jury's presence.8

  4. If the patient has died

    In Pennsylvania, under the Medical Care Availability and Reduction of Error (MCARE) Act, 40 P.S. § 1303.513(d), a medical malpractice claim brought as a wrongful death or survival action must be commenced within two years after the death, in the absence of affirmative misrepresentation or fraudulent concealment of the cause of death.9 In Dubose v. Quinlan, 173 A.3d 634 (Pa. 2017), the Supreme Court of Pennsylvania held that this two-year period runs from the death.10 In New Jersey, a wrongful death action generally must be commenced within two years after the death, under N.J.S.A. 2A:31-3.11

  5. Claims for children

    Claims brought for a child follow different rules in both states.512

  6. Filing suit (Pennsylvania)

    Under Pa.R.C.P. 1042.3(a), a professional negligence claim needs a certificate of merit, filed with the complaint or within sixty days after filing.13

  7. After the defendant answers (New Jersey)

    Under N.J.S.A. 2A:53A-27, a malpractice plaintiff must give each defendant an affidavit of an appropriate licensed person within 60 days after the answer, and the court may grant one more period of up to 60 days for good cause.14

The Pennsylvania certificate must state one of the rule's alternatives.13 One is a licensed professional's written statement that there is a reasonable probability the care fell outside acceptable professional standards and that such conduct was a cause in bringing about the harm.13 Another is that expert testimony is unnecessary for the claim.13

The seven-year repose. In Yanakos v. UPMC, decided October 31, 2019, the Supreme Court of Pennsylvania held that the MCARE Act's seven-year statute of repose, 40 P.S. § 1303.513(a), is unconstitutional, so that seven-year cutoff is not enforced.15 A statute of repose is an outer time limit that can end a claim before the harm is found. Three justices dissented, and the court later denied reargument.1516

Immunity for acting in good faith. Each state's anatomical gift law protects people who follow it in good faith.

Pennsylvania. Under 20 Pa.C.S. § 8616(c), a person who acts in good faith in accordance with the anatomical gift law is not liable for damages in any civil action for that act.17 That immunity does not extend to acts or omissions resulting from gross negligence, recklessness or intentional misconduct.17 This text comes from Act 90 of 2018, whose amendment of § 8616 took effect on publication of a notice under 20 Pa.C.S. § 8629.17 That notice was published in the Pennsylvania Bulletin on October 26, 2019, at 49 Pa.B. 6491, so the 2018 text has applied since that date.1819

New Jersey. N.J.S.A. 26:6-91(a) makes a person or entity immune from liability for actions taken in accordance with, or in a good faith attempt to act in accordance with, the anatomical gift act.20

When the two years start, and whether an immunity applies, turn on facts a lawyer will want to see.

Questions about how this affects you?

If you or someone in your family was hurt and you want to understand your options, you can talk with a lawyer at CM Injury at (267) 936-2233. The conversation is free and confidential.

Frequently asked questions

Is cancer from a donor organ common?

No. For 2012 to 2017, the U.S. Disease Transmission Advisory Committee found unexpected proven or probable donor-derived cancer in 2.6 of every 10,000 transplant recipients.

Should my donor have been screened for cancer?

Current OPTN policy requires the host OPO to seek the donor's medical and behavioral history, review the medical record and examine the donor, and the history must include the results of any testing used to identify malignancies. The policy names no particular cancer screen, and programs must tell candidates there is no comprehensive way to screen donors for all transmissible diseases.

Was I supposed to be told about this risk?

Yes. Programs must explain the general risks of malignancy transmission from donors and document your informed consent.

How long do I have to bring a claim?

Generally two years in each state: Pennsylvania under 42 Pa.C.S. § 5524(2), and New Jersey from when the cause of action accrued, under N.J.S.A. 2A:14-2(a). Shorter deadlines can apply to some claims. Both states have a discovery rule that can hold off the start of that period while you reasonably could not have known of the injury and its possible cause. Claims after a death and claims for children follow different rules.

Can the donor's family be held responsible?

In New Jersey, neither the person making an anatomical gift nor the donor's estate is liable for injury that results from the making or use of the gift. Pennsylvania's 2018 text of 20 Pa.C.S. § 8616(c)(3) says the same, and that text has applied since October 26, 2019.

Sources

  1. Systematic review, PMC8842379ncbi.nlm.nih.govRetrieved November 10, 2026
  2. UK SaBTO guidance: Transplantation of organs from deceased donors with cancer or a history of cancerassets.publishing.service.gov.ukRetrieved November 10, 2026
  3. OPTN Policies PDF (Internet Archive capture of hrsa.gov/sites/default/files/hrsa/optn/optn_policies.pdf)web.archive.orgRetrieved November 10, 2026
  4. 42 Pa.C.S. § 5524 (Two year limitation), palegis.us official textPennsylvania General Assembly (palegis.us)Retrieved November 10, 2026
  5. N.J.S.A. 2A:14-2 (lis.njleg.state.nj.us, official NJ statutes)New Jersey LegislatureRetrieved November 10, 2026
  6. Kaul DR et al., Ten years of donor-derived disease: A report of the Disease Transmission Advisory Committee, Am J Transplant 2021;21:689-702 (copy in WHO NOTIFY Library)notifylibrary.orgRetrieved November 10, 2026
  7. Nicolaou v. Martin, No. 44 MAP 2017 (Pa. 2018), majority opinion (pacourts.us)Unified Judicial System of Pennsylvania (pacourts.us)Retrieved November 10, 2026
  8. Lopez v. Swyer, 62 N.J. 267 (1973)Caselaw Access Project (static.case.law)Retrieved November 13, 2026
  9. MCARE Act, section 513 (40 P.S. § 1303.513), official textPennsylvania General AssemblyRetrieved November 13, 2026
  10. Dubose v. Quinlan, 173 A.3d 634 (Pa. 2017)Caselaw Access Project (static.case.law)Retrieved November 13, 2026
  11. N.J.S.A. 2A:31-3 (lis.njleg.state.nj.us, official NJ statutes)New Jersey LegislatureRetrieved November 13, 2026
  12. 42 Pa.C.S. § 5533 (Infancy, insanity or imprisonment), palegis.us official textPennsylvania General Assembly (palegis.us)Retrieved November 13, 2026
  13. Pa.R.C.P. 1042.3 (Certificate of Merit), Pennsylvania Codepacodeandbulletin.govRetrieved November 10, 2026
  14. P.L.2004, c.17 (N.J. medical malpractice reform; amends N.J.S.A. 2A:53A-27), official chapter lawNew Jersey LegislatureRetrieved November 10, 2026
  15. Yanakos v. UPMC, No. 10 WAP 2018 (Pa. Oct. 31, 2019), majority opinion (pacourts.us)Unified Judicial System of Pennsylvania (pacourts.us)Retrieved November 10, 2026
  16. Yanakos v. UPMC, No. 10 WAP 2018, dissenting statement on reargument (pacourts.us)Unified Judicial System of Pennsylvania (pacourts.us)Retrieved November 13, 2026
  17. 20 Pa.C.S. § 8616 (Rights and duties at death), palegis.us official textPennsylvania General Assembly (palegis.us)Retrieved November 10, 2026
  18. 20 Pa.C.S. § 8629 (Department of Transportation), palegis.us official textPennsylvania General Assembly (palegis.us)Retrieved November 13, 2026
  19. Implementation of Act 90 of 2018, 49 Pa.B. 6491 (Pennsylvania Bulletin, October 26, 2019)Pennsylvania Bulletin (pacodeandbulletin.gov)Retrieved November 13, 2026
  20. P.L.2008, c.50 (N.J. Revised Uniform Anatomical Gift Act), official chapter lawNew Jersey LegislatureRetrieved November 10, 2026
  21. 45 CFR 164.524 Access of individuals to protected health information (LII)Legal Information Institute, Cornell Law SchoolRetrieved November 10, 2026

Attorney Advertising. CM Injury (Cavaliere & Mangiaracina, PLLC), 161 Washington Street, Suite 1010, Conshohocken, PA 19428. Reviewed by Frank Mangiaracina. (267) 936-2233.

This article is general information, not legal advice, and reading it does not create an attorney-client relationship. Laws change and every case turns on its own facts.

Images: Photograph, National Cancer Institute (public domain); Illustration.

We Win Big
Tell Us What Happened

Free, no obligation.